NCT07055373 Transauricular Vagus Nerve Stimulation for Chronic Whiplash Associated Disorders
| NCT ID | NCT07055373 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Calgary |
| Condition | Whiplash Associated Disorder (WAD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-01-21 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-01-21 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Approximately 50% of people with chronic whiplash-associated disorders (WAD) continue to report the presence of symptoms 12 months post-injury. These symptoms include high levels of pain and disability as well as psychological symptoms such as post-traumatic stress. The nervous system may also be affected, specifically the autonomic nervous system which is responsible for regulating heart rate and blood pressure. An important part of the autonomic system is the vagus nerve, which helps regulate pain and stress responses. Treatment of this nerve via transauricular vagal nerve stimulation (taVNS) has been shown to improve health outcomes in many pain conditions such as chronic low back pain and postural tachycardia syndrome. TaVNS works by sending mild electrical pulses through the ear. This project aims to explore whether or not taVNS can help people with chronic whiplash-associated disorders (WAD) feel better. The first goal is to evaluate the safety and feasibility of taVNS. The investigators are interested in learning how many people with chronic WAD participate in the study and how many complete the full treatment, as well as ensuring that the treatment does not cause any serious side effects. An additional goal is to evaluate the effects of taVNS on neck pain intensity and associated disability, pain sensitivity, heart rate variability, blood pressure, quality of life, post-traumatic stress, stress, anxiety, and depression as measured by questionnaires and physical assessments, as compared to those assigned to the sham treatment.
Eligibility Criteria
Inclusion Criteria: 1. Symptom duration ≥3 months and \<10 years; and 2. Classifiable as WAD grade I (neck pain without physical impairments) or II (neck pain \& impairment such as movement loss and/or tenderness) or III (neck pain \& neurological deficit evident on physical exam); 3. Average pain intensity (over one week) ≥ 4/10; 4. Neck Disability Index score \> 28% (14/50). Exclusion Criteria: 1. WAD IV injury (no neurological deficit, fracture, or dislocation); 2. Concussion symptoms; 3. Patients who have undergone cervical vagotomy; 4. Patients diagnosed with severe bradycardia; 5. Patients with a permanent implanted metallic or electronic device or jewellery at close proximity to the ear tragus; 6. Patients with any active implanted device (including electronic and/or medical devices) e.g. cochlear implant, cerebral shunts, invasive vagus nerve stimulators, or non-active but potentially interacting with the nervous system (e.g., metal implants); 7. Open wounds or rashes, swollen, red, infected, or inflamed areas or skin eruptions (e.g., phlebitis, thrombophlebitis, varicose veins); or cancerous lesions in the area of stimulation 8. Using medications associated with ANS function such as Beta Blockers; 9. Adverse general health factors such as presence of a neurological disorder (e.g., multiple sclerosis), inflammatory condition (e.g., rheumatoid arthritis), cardiovascular disorder (known severe coronary disease or recent myocardial infarction (within 5 years)); metabolic disorder (e.g., diabetes), visual deficit or disease process (e.g. cataracts, double or blurred vision), known or suspected serious spinal pathology (e.g. metastatic disease of the spine), pregnancy, or previous spinal surgery or recurrent treatment for spinal disorders; 10. History of any mental health conditions prior to the MVC, such as bipolar disorder, schizophrenia, anxiety, PTSD or severe depression; 11. People who are unable to complete the questionnaires.
Contact & Investigator
Ashley Smith
PRINCIPAL INVESTIGATOR
University of Calgary
Frequently Asked Questions
Who can join the NCT07055373 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Whiplash Associated Disorder (WAD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07055373 currently recruiting?
Yes, NCT07055373 is actively recruiting participants. Contact the research team at jennifer.laxshimalla@vivocura.ca for enrollment information.
Where is the NCT07055373 trial being conducted?
This trial is being conducted at Calgary, Canada.
Who is sponsoring the NCT07055373 clinical trial?
NCT07055373 is sponsored by University of Calgary. The principal investigator is Ashley Smith at University of Calgary. The trial plans to enroll 40 participants.